AIMS: Transient outward potassium current (I(to)) is thought to be central to the pathogenesis of the Brugada syndrome (BrS). However, an I((to)) activator has not been available with which to validate this hypothesis. Here, we provide a direct test of the hypothesis using a novel I(to) activator, NS5806. METHODS AND RESULTS: Isolated canine ventricular myocytes and coronary-perfused wedge preparations were used. Whole-cell patch-clamp studies showed that NS5806 (10 microM) increased peak I(to) at +40 mV by 79 +/- 4% (24.5 +/- 2.2 to 43.6 +/- 3.4 pA/pF, n = 7) and slowed the time constant of inactivation from 12.6 +/- 3.2 to 20.3 +/- 2.9 ms (n = 7). The total charge carried by I(to) increased by 186% (from 363.9 +/- 40.0 to 1042.0 +/- 103.5 pA x ms/pF, n = 7). In ventricular wedge preparations, NS5806 increased phase 1 and notch amplitude of the action potential in the epicardium, but not in the endocardium, and accentuated the ECG J-wave, leading to the development of phase 2 re-entry and polymorphic ventricular tachycardia (n = 9). Although sodium and calcium channel blockers are capable of inducing BrS only in right ventricular (RV) wedge preparations, the I(to) activator was able to induce the phenotype in wedges from both ventricles. NS5806 induced BrS in 4/6 right and 2/10 left ventricular wedge preparations. CONCLUSION: The I(to) activator NS5806 recapitulates the electrographic and arrhythmic manifestation of BrS, providing evidence in support of its pivotal role in the genesis of the disease. Our findings also suggest that a genetic defect leading to a gain of function of I(to) could explain variants of BrS, in which ST-segment elevation or J-waves are evident in both right and left ECG leads.
AIMS: Transient outward potassium current (I(to)) is thought to be central to the pathogenesis of the Brugada syndrome (BrS). However, an I((to)) activator has not been available with which to validate this hypothesis. Here, we provide a direct test of the hypothesis using a novel I(to) activator, NS5806. METHODS AND RESULTS: Isolated canine ventricular myocytes and coronary-perfused wedge preparations were used. Whole-cell patch-clamp studies showed that NS5806 (10 microM) increased peak I(to) at +40 mV by 79 +/- 4% (24.5 +/- 2.2 to 43.6 +/- 3.4 pA/pF, n = 7) and slowed the time constant of inactivation from 12.6 +/- 3.2 to 20.3 +/- 2.9 ms (n = 7). The total charge carried by I(to) increased by 186% (from 363.9 +/- 40.0 to 1042.0 +/- 103.5 pA x ms/pF, n = 7). In ventricular wedge preparations, NS5806 increased phase 1 and notch amplitude of the action potential in the epicardium, but not in the endocardium, and accentuated the ECG J-wave, leading to the development of phase 2 re-entry and polymorphic ventricular tachycardia (n = 9). Although sodium and calcium channel blockers are capable of inducing BrS only in right ventricular (RV) wedge preparations, the I(to) activator was able to induce the phenotype in wedges from both ventricles. NS5806 induced BrS in 4/6 right and 2/10 left ventricular wedge preparations. CONCLUSION: The I(to) activator NS5806 recapitulates the electrographic and arrhythmic manifestation of BrS, providing evidence in support of its pivotal role in the genesis of the disease. Our findings also suggest that a genetic defect leading to a gain of function of I(to) could explain variants of BrS, in which ST-segment elevation or J-waves are evident in both right and left ECG leads.
Authors: José M Di Diego; Jonathan M Cordeiro; Robert J Goodrow; Jeffrey M Fish; Andrew C Zygmunt; Guillermo J Pérez; Fabiana S Scornik; Charles Antzelevitch Journal: Circulation Date: 2002-10-08 Impact factor: 29.690
Authors: Jonathan M Cordeiro; Lindsey Greene; Cory Heilmann; Daniel Antzelevitch; Charles Antzelevitch Journal: Am J Physiol Heart Circ Physiol Date: 2003-12-11 Impact factor: 4.733
Authors: Charles Antzelevitch; Guido D Pollevick; Jonathan M Cordeiro; Oscar Casis; Michael C Sanguinetti; Yoshiyasu Aizawa; Alejandra Guerchicoff; Ryan Pfeiffer; Antonio Oliva; Bernd Wollnik; Philip Gelber; Elias P Bonaros; Elena Burashnikov; Yuesheng Wu; John D Sargent; Stefan Schickel; Ralf Oberheiden; Atul Bhatia; Li-Fern Hsu; Michel Haïssaguerre; Rainer Schimpf; Martin Borggrefe; Christian Wolpert Journal: Circulation Date: 2007-01-15 Impact factor: 29.690
Authors: Barry London; Michael Michalec; Haider Mehdi; Xiaodong Zhu; Laurie Kerchner; Shamarendra Sanyal; Prakash C Viswanathan; Arnold E Pfahnl; Lijuan L Shang; Mohan Madhusudanan; Catherine J Baty; Stephen Lagana; Ryan Aleong; Rebecca Gutmann; Michael J Ackerman; Dennis M McNamara; Raul Weiss; Samuel C Dudley Journal: Circulation Date: 2007-10-29 Impact factor: 29.690
Authors: H Tanaka; O Kinoshita; S Uchikawa; H Kasai; M Nakamura; A Izawa; O Yokoseki; H Kitabayashi; W Takahashi; Y Yazaki; N Watanabe; H Imamura; K Kubo Journal: Pacing Clin Electrophysiol Date: 2001-08 Impact factor: 1.976
Authors: Jared Tur; Kalyan C Chapalamadugu; Christopher Katnik; Javier Cuevas; Aruni Bhatnagar; Srinivas M Tipparaju Journal: Am J Physiol Heart Circ Physiol Date: 2016-12-16 Impact factor: 4.733
Authors: Yoshino Minoura; Brian K Panama; Vladislav V Nesterenko; Matthew Betzenhauser; Hector Barajas-Martínez; Dan Hu; José M Di Diego; Charles Antzelevitch Journal: Heart Rhythm Date: 2013-03-14 Impact factor: 6.343
Authors: Nicole J Boczek; Dan Ye; Eric K Johnson; Wei Wang; Lia Crotti; David J Tester; Federica Dagradi; Yuka Mizusawa; Margherita Torchio; Marielle Alders; John R Giudicessi; Arthur A M Wilde; Peter J Schwartz; Jeanne M Nerbonne; Michael J Ackerman Journal: Circ Res Date: 2014-06-24 Impact factor: 17.367